Clinical Trial Results:
Doppelblinde, randomisierte, prospektive multizentrische klinische Studie zur Definition der optimalen antibiotischen Therapiedauer bei Patienten mit unkomplizierter akuter Cholangitis: Moxifloxacin oral vs. Placebo oral nach Entfieberung zur Fortführung der initial intravenösen Therapie mit Moxifloxacin.
Duration of Moxifloxacin therapy for acute cholangitis –
a randomized, placebo-controlled, multicenter study.
The MONA LISA study.
Summary
|
|
EudraCT number |
2005-004851-37 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
04 Aug 2022
|
First version publication date |
04 Jun 2022
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
Summary of Clinical Trial Report |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.